Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2022 14:00 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors

CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
August 17, 2022 08:30 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
August 15, 2022 16:00 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Closed private placement in April 2022, with net proceeds of approximately $6.9 millionSigned multiple strategic agreements and collaborations to further vaccine candidate research, development, and...
August 11, 2022 13:47 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules

CINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
August 09, 2022 08:00 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces $10 Million Private Placement Priced At-the-Market under Nasdaq Rules

CINCINNATI, Ohio, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to...
July 20, 2022 14:00 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children’s Hospital Medical Center for S&P Vaccine Platform Development

CINCINNATI, July 20, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
June 06, 2022 10:30 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
May 31, 2022 08:30 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford

CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
May 19, 2022 14:00 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration...
May 13, 2022 17:01 ET | Source: Blue Water Vaccines Inc.

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...